Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study - Efficacy of Amifostine in Alleviating Toxicity Associated With Targeted Supradose Cisplatin and Concomitant Radiation Therapy (RADPLAT) in Head and Neck Cancer

NCT00003580 is registered in ClinicalTrials.gov with University of Tennessee as lead sponsor.

NCT NCT00003580
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00003580 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study - Efficacy of Amifostine in Alleviating Toxicity Associated With Targeted Supradose Cisplatin and Concomitant Radiation Therapy (RADPLAT) in Head and Neck Cancer
Lead sponsor
University of Tennessee
Phase
Phase 2
Overall status
Completed
Start date
June 30, 1998
Completion date
May 31, 2004
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

drug/agent toxicity by tissue/organ, head and neck cancer, oral complications, radiation toxicity